Patents by Inventor Mark R. Karver

Mark R. Karver has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Drug delivery vehicles for atherosclerosis nanomedicine
    Patent number: 12214076
    Abstract: Provided herein are peptide amphiphiles (PAs). In some embodiments, provided herein are targeting PAs comprising a PA backbone and a targeting moiety. In some embodiments, provided herein are therapeutic PAs comprising a PA backbone and a therapeutic agent. In some embodiments, the peptide amphiphiles are co-assembled into nanofibers. In some embodiments, the nanofibers may be used for the treatment of atherosclerosis or related disease.
    Type: Grant
    Filed: February 17, 2020
    Date of Patent: February 4, 2025
    Assignees: Northwestern University, The University of North Carolina at Chapel Hill
    Inventors: Samuel I. Stupp, Melina R. Kibbe, Mark R. Karver, Erica B. Peters, Miranda So, Neel Anand Mansukhani, Mazen Albaghdadi, Nick D. Tsihlis
  • Functionalized 1,2,4,5-tetrazine compounds for use in bioorthogonal coupling reactions
    Patent number: 11208390
    Abstract: The present application relates to functionalized 1,2,4,5-tetrazine compounds. The compounds are useful in compositions and methods using bioorthogonal inverse electron demand Diels-Alder cycloaddition reactions for the rapid and specific covalent delivery of a “payload” to a ligand bound to a biological target.
    Type: Grant
    Filed: March 2, 2020
    Date of Patent: December 28, 2021
    Assignee: The General Hospital Corporation
    Inventors: Scott A. Hilderbrand, Neal K. Devaraj, Ralph Weissleder, Mark R. Karver
  • DRUG DELIVERY VEHICLES FOR ATHEROSCLEROSIS NANOMEDICINE
    Publication number: 20200289416
    Abstract: Provided herein are peptide amphiphiles (PAs). In some embodiments, provided herein are targeting PAs comprising a PA backbone and a targeting moiety. In some embodiments, provided herein are therapeutic PAs comprising a PA backbone and a therapeutic agent. In some embodiments, the peptide amphiphiles are co-assembled into nanofibers. In some embodiments, the nanofibers may be used for the treatment of atherosclerosis or related disease.
    Type: Application
    Filed: February 17, 2020
    Publication date: September 17, 2020
    Inventors: Samuel I. Stupp, Melina R. Kibbe, Mark R. Karver, Erica B. Peters, Miranda So, Neel Anand Mansukhani, Mazen Albaghdadi
  • FUNCTIONALIZED 1,2,4,5-TETRAZINE COMPOUNDS FOR USE IN BIOORTHOGONAL COUPLING REACTIONS
    Publication number: 20200199085
    Abstract: The present application relates to functionalized 1,2,4,5-tetrazine compounds. The compounds are useful in compositions and methods using bioorthogonal inverse electron demand Diels-Alder cycloaddition reactions for the rapid and specific covalent delivery of a “payload” to a ligand bound to a biological target.
    Type: Application
    Filed: March 2, 2020
    Publication date: June 25, 2020
    Inventors: Scott A. Hilderbrand, Neal K. Devaraj, Ralph Weissleder, Mark R. Karver
  • Functionalized 1,2,4,5-tetrazine compounds for use in bioorthogonal coupling reactions
    Patent number: 10611738
    Abstract: The present application relates to functionalized 1,2,4,5-tetrazine compounds. The compounds are useful in compositions and methods using bioorthogonal inverse electron demand Diels-Alder cycloaddition reactions for the rapid and specific covalent delivery of a “payload” to a ligand bound to a biological target.
    Type: Grant
    Filed: February 26, 2018
    Date of Patent: April 7, 2020
    Assignee: The General Hospital Corporation
    Inventors: Scott A. Hilderbrand, Neal K. Devaraj, Ralph Weissleder, Mark R. Karver
  • FUNCTIONALIZED 1,2,4,5-TETRAZINE COMPOUNDS FOR USE IN BIOORTHOGONAL COUPLING REACTIONS
    Publication number: 20190040021
    Abstract: The present application relates to functionalized 1,2,4,5-tetrazine compounds. The compounds are useful in compositions and methods using bioorthogonal inverse electron demand Diels-Alder cycloaddition reactions for the rapid and specific covalent delivery of a “payload” to a ligand bound to a biological target.
    Type: Application
    Filed: February 26, 2018
    Publication date: February 7, 2019
    Inventors: Scott A. Hilderbrand, Neal K. Devaraj, Ralph Weissleder, Mark R. Karver
  • Functionalized 1,2,4,5-tetrazine compounds for use in bioorthogonal coupling reactions
    Patent number: 9902705
    Abstract: The present application relates to functionalized 1,2,4,5-tetrazine compounds. The compounds are useful in compositions and methods using bioorthogonal inverse electron demand Diels-Alder cycloaddition reactions for the rapid and specific covalent delivery of a “payload” to a ligand bound to a biological target.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: February 27, 2018
    Assignee: The General Hospital Corporation
    Inventors: Scott A. Hilderbrand, Neal K. Devaraj, Ralph Weissleder, Mark R. Karver
  • FUNCTIONALIZED 1,2,4,5-TETRAZINE COMPOUNDS FOR USE IN BIOORTHOGONAL COUPLING REACTIONS
    Publication number: 20150246893
    Abstract: The present application relates to functionalized 1,2,4,5-tetrazine compounds. The compounds are useful in compositions and methods using bioorthogonal inverse electron demand Diels-Alder cycloaddition reactions for the rapid and specific covalent delivery of a “payload” to a ligand bound to a biological target.
    Type: Application
    Filed: March 14, 2013
    Publication date: September 3, 2015
    Applicant: The General Hospital Corporation
    Inventors: Neal K. Devaraj, Mark R. Karver, Scott A. Hilderbrand, Ralph Weissleder